Agilent plans to pay approximately €68 million in cash, and the deal is expected to be completed by mid-January.
Transcriptic will incorporate several of Agilent's genome engineering reagents into its cloud-based, remote access, automated biology research platform.
Agilent reported total revenues of $1.11 billion, up from $1.04 billion in the third quarter of 2015, and besting the average analyst estimate for revenues of $1.07 billion.
In addition to Illumina and Thermo Fisher, the investment bank reinitiated coverage of Bruker, Invitae, Agilent, Waters, and T2 Biosystems.
Agilent and CRO PureHoney will develop new applications for the RapidFire 365 system, including workflows for pharmaceutical research, forensics, and metabolomics.
The FDA has approved Merck's Keytruda as a first-line treatment for non-small cell lung cancer in patients with high PD-L1 expression.
China-based Burning Rock will develop cancer diagnostics for Chinese patients based on the Agilent SureSelect target enrichment system.
The firm plans to use the funds to repay outstanding debts and for general corporate purposes.
The firm has not disclosed the amount it is seeking, but said it plans to use the funds to repay outstanding debts and for general corporate purposes.
Growth in Agilent's CrossLab Group and Diagnostics and Genomic Group partially offset a decline for its Life Sciences and Applied Markets Group.
A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.
The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.
University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.
In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.